Does flow cytometry crossmatch predict renal allograft outcome in patients with a negative antiglobulin crossmatch?
J Michael Cecka
Correspondence UCLA Immunogenetics Center, 1000 Veteran Avenue 15–20, Los Angeles, CA 90095, USA
Email mcecka@ucla.edu
This article has no abstract so we have provided the first paragraph of the full text.
The risks associated with preformed antidonor human leukocyte antigen (HLA) antibodies in renal transplant candidates have been well documented.1 By routinely performing simple crossmatch tests before transplantation, irreversible hyperacute rejection resulting from high levels of circulating cytotoxins has been almost completely eliminated. Nevertheless, the antibody response is dynamic and even when antibody levels have fallen, long after the immunizing event, they can rise again within days after transplantation as a result of engagement of immune memory. The consequences include early humoral rejection that is difficult to manage with current immunosuppression alone, and perhaps lasting damage that will ultimately shorten the graft survival time.
Full text of this article is available with one of the following:
- Membership of the International Society of Nephrology. If already a member, please login. If not please join the Society now
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please login for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or login above.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
